Abstract Library

#4663 CAREFNDR: A phase III, randomised, parallel group, placebo-controlled study to evaluate the efficacy and safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumours

Introduction: Paltusotine is a once-daily, oral, nonpeptide, selective SST2 receptor agonist in development for carcinoid syndrome (CS) treatment. In a Phase 2, open-label, dose-ranging study, paltusotine reduced the frequency and severity of CS symptoms and was well tolerated (NCT05361668).

Conference:

Presenting Author:

Authors: Kim R, Usiskin K, Fan X, Quock T, Mui C,

Keywords: paltusotine, phase 3 trial, somatostatin receptor agonist, neuroendocrine tumour, carcinoid syndrome,

#4597 FIT-NETs: Assessing the effects of an exercise programme on the physical and emotional well-being of patients with advanced G1-2 NETs of GEP or unknown origin

Introduction: Physical activity programs in solid tumours have shown to improve symptom control and even survival, but their impact on NENs remains unexplored. Advanced disease, systemic therapy, and hormonal secretion in these tumours often lead to muscle wasting and sarcopenia.

Conference:

Presenting Author: Anton-Pascual B

Authors: Anton-Pascual B, Rodriguez-Gomez J, de Cima A, Herrero-Llorente A, Modrego A,

Keywords: FIT-NET, physical exercise program, Quadriceps, MEP & MIP, QoL,

#4458 Survival and optimal follow-up cut-off of lung neuroendocrine tumours after surgery: Experience of a high-volume centre over 25 years

Introduction: Surgery is the curative therapy for lung neuroendocrine tumours (NET). Follow-up protocols after surgery are not evidence based and factors affecting survival are not clear.

Conference:

Presenting Author: Mortagy M

Authors: Mortagy M, El Asmar M, Nonaka D, Dolly S, Srirajaskanthan R,

Keywords: Lung NET, Lung NET Surgery, Follow-up after surgery,

#4447 Efficacy and safety analysis of XELOX plus bevacizumab in the treatment of metastatic NETs

Introduction: For patients with advanced NETs, standardised treatment protocols based on guideline consensus form the foundation, yet individualised interpretation and flexible application of these guidelines are essential.

Conference:

Presenting Author: Wang H

Authors: Wang H, Zhou Y, Tan H, Sun Y, Chi Y,

Keywords: advanced neuroendocrine tumour, combination therapy, drug therapy, retrospective study, combined chemotherapy targeting,

#4412 25-years of experience with somatostatin receptor-based therapy in patients with small intestinal neuroendocrine tumours

Introduction: Small intestinal neuroendocrine tumours are well-differentiated and express type 2 somatostatin receptors (SSTR2). Treatment with somatostatin analogues (SSA) (octreotide or lanreotide) has been a cornerstone in controlling tumour growth for 25 years. Peptide Receptor Radionuclide Therapy (PRRT), utilising radiolabelled SSA, was introduced in our institution in May 2009 as primarily 2nd line treatment after progression on SSA. The standard PRRT regimen includes 4 cycles of PRRT (7.4 GBq 177Lu-DOTATATE every eight weeks). Re-treatment protocols remain debated.

Conference:

Presenting Author: Andreassen M

Authors: Slott C, Oturai P, Langer S, Møller S, Hansen C,

Keywords: SSA, PRRT, small intestinal NET,